The Quotes are Powered By Forexpros, the Forex, Futures, and Stock Markets Portal.

Recombinant vaccine from Protein Sciences receives FDA approval

Thursday, 17 January 2013
The US Food and Drug Administration has approved Protein Sciences Corporation’s vaccine Flublok for the prevention of seasonal influenza in adults 18 to 49 years of age. Diamyd Medical holds about 8 percent of the shares in Protein Sciences Corporation.

Flublok is a recombinant protein-based seasonal influenza vaccine and the first influenza vaccine manufactured using recombinant technology that has received marketing approval by the FDA. Protein Sciences Corporation is planning to have a limited launch of the product in February 2013 with the full launch occurring in time for the 2013/14 influenza season. More information can be found at protein science or Flublok
Based on press release from the company

We welcome your contribution. Did you find anything wrong with this article? Do you want to contribute to our news network? Do have a news tip or assist us with a correction